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Abstract Similar to Parkinson disease, multiple system
atrophy (MSA) presents neuropathologically with nigral
neuronal loss; however, the hallmark intracellular α-
synuclein (αSyn) accumulation in MSA affects typically
oligodendrocytes to form glial cytoplasmic inclusions.
The underlying pathogenic mechanisms remain unclear.
As MSA is predominantly sporadic, epigenetic mecha-
nisms may play a role. We tested the effects of the pan-
his tone deacetylase inhibi tor (HDACi) sodium
phenylbutyrate in aged mice overexpressing αSyn under
the control of the proteolipid protein promoter
(PLP–αSyn) designed to model MSA and characterized
by αSyn accumulation in oligodendrocytes and nigral
neurodegeneration. HDACi improved motor behavior
and survival of nigral neurons in PLP–αSyn mice.
Furthermore, HDACi reduced the density of oligoden-
droglial αSyn aggregates, which correlated with the sur-
vival of nigral neurons in PLP–αSyn mice. For the first
time, we suggest a role of HDACi in the pathogenesis
of MSA-like neurodegeneration and support the future
development of selective HDACi for MSA therapy.
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Introduction
Recently, histone acetylation has been implicated in the
pathogenesis of various neurodegenerative diseases
[1–3] . His tone ace ty l t r ans fe rases and h is tone
deacetylases (HDACs) mediate histone acetylation and
deacetylation. They support chromatin stability and pro-
vide an important epigenetic mechanism for modulation
of gene transcription, which may play a role in the
pathogenesis of predominantly non-genetic disorders.
Multiple system atrophy (MSA) is a sporadic neurode-
generative disease that includes autonomic failure, par-
kinsonism, and cerebellar ataxia, in any combination,
reflecting multisystem neuronal loss, gliosis, and α-
synuclein (αSyn) pathology [4, 5]. αSyn-positive glial
cytoplasmic inclusions (GCIs) represent the pathological
hallmark of MSA and classify MSA as one of the α-
synucleinopathies, together with Parkinson’s disease
(PD) and dementia with Lewy bodies [6]. The location
of αSyn inclusions in MSA brains is not limited to the
oligodendroglial cytoplasm but can be found in nuclear
inclusions in neuronal, as well as in glial cells [7, 8].
αSyn interacts with histones in the nucleus, leading to
inhibition of acetylation and finally resulting in neuro-
toxicity [9]. Therefore, we hypothesize that αSyn in
MSA may interfere with histone acetylation in glial
and neuronal cells and that this may play a role in
the disease process, thus representing a new potential
therapeutic target. To test this hypothesis, we sought
to analyze the effects of sodium phenylbutyrate
(NaPB), a nonselective pan-HDAC inhibitor (HDACi)
in a transgenic mouse model of MSA, based on
targeted overexpression of full-length human αSyn un-
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Animals and Drug Treatment
We housed MSA transgenic mice with targeted overexpres-
sion of human αSyn under the PLP promoter (henceforth
referred to as PLP–αSyn mice and previously described
[10]), as well as nontransgenic sex- and age-matched controls
of the background strain C57Bl/6 in a temperature-controlled
room under a 12-h light/dark cycle. Mice had free access to
water and food at the specific pathogen-free animal facility of
the Medical University Innsbruck. We undertook all efforts
possible to minimize the number and suffering of animals
used. We performed all animal procedures according to
Austrian Law and approved by the Federal Ministry of
Science and Research, Austria. We genotyped mice by ear
punching followed by DNA isolation and polymerase chain
reaction for human αSyn with specific primers (forward: 5’-
ATG GAT GTA TTC ATG AAA GG-3’; reverse: 5’-TTA
GGC TTC AGG TTC GTA G-3’) resulting in a 450-base pair
polymerase chain reaction product. We randomized transgen-
ic, as well as nontransgenic controls of the background strain
C57Bl/6, mice at the age of 9 months, based on their weight,
into 2 treatment groups. Treatment consisted of daily intraper-
itoneal injections of either 200 mg/kg body weight of NaPB
(Santa Cruz Biotechnology, Heidelberg, Germany) in saline or
vehicle only over 8 weeks. The dose and duration of treatment
were based on data from previous experimental studies
reporting neuroprotection by NaPB [11].
To assess the effects of the interventions, we assessed by
behavioral tests the motor abil i t ies of the mice.
Immunoblotting and immunohistochemistry were performed
to analyze the neuropathological status of substantia nigra pars
compacta (SNc) after treatment, as described in the following
protocols (Fig. 1).
Gait Analysis
We performed motor behavior analysis immediately after
completing daily NaPB/vehicle treatment (week 9). We used
the DigiGait Analysis System (Mouse Specifics, Quincy, MA,
USA) to measure the stride length of the animals. We placed
the mice on a motorized transparent treadmill belt and record-
ed the animals’ gait at a speed of 25 cm/s from underneath,
generating digital paw prints that were analyzed with the spe-
cific DigiGait Software 9.0 (Mouse Specifics), resulting in the
mean stride length of each mouse.
Chemicals and Antibodies
We obtained paraformaldehyde, phosphate-buffered saline
(PBS), sucrose, H2O2, Trizma hydrochloride Ultra, trichloro-
acetic acid, acetone, bicinchoninic acid solution, copper (II)
sulfate-pentahydrate, Ponceau-Red, Tween-20, sodium dode-
cyl sulfate, 2-β-mercaptoethanol, 3,3’-diaminobenzidine ben-
zidine tetrahydrochloride, bovine serum albumin (BSA), and
cresyl violet acetate from Sigma-Aldrich (Vienna, Austria).
NaOH pellets, 2-methylbutan Uvasol for Spectroscopy,
Entellan, ethylenediaminetetraacetic acid, Triton X-100, and
acetic acid were from Merck (Darmstadt, Germany). Bis-Tris
(10%) gels, 10× NuPAGE Sample Reducing Agent, 4×
NuPAGE LDS Sample Buffer, 20× NuPAGE SDS MES
Running Buffer, NuPAGE Antioxidant, SeeBlue Pre-stained
Protein Standard, MagicMark XP Western Protein Standard,
and 20× NuPAGE Transfer Buffer were obtained from Novex
Life Technologies (formerly Invitrogen, San Diego, CA,
USA). NaOH and ethanol were from VWR (Radnor, PA,
USA), 37% hydrochloric acid, n-butylacetate, NaCl, and
96% sulfuric acid were obtained from Roth (Karlsruhe,
Germany). Thiopental was obtained from Sandoz (Kundl,
Austria); methanol was from Fisher Scientific (Vienna,
Austria); Amersham ECL Prime Blocking Agent and nitrocel-
lulose membranes from GE Healthcare Bio-Sciences AB
(Uppsala, Sweden); Western Bright Quantum from Advansta
(Menlo Park, CA, USA), deoxycholic acid sodium salt from
Fluka (Buchs, Switzerland); and Complete ULTRA Tablets
(proteinase inhibitor cocktail with phenylmethylsulfonyl fluo-
ride) was from Roche (Basel, Switzerland). Normal goat and
horse serum was purchased from Gibco Life Technologies
(San Diego, CA, USA).
We purchased polyclonal rabbit anti-DJ1/PARK7 (1:2000),
polyclonal rabbit anti-acetyl-histone H3 (acH3; Lys9/18, 1:10,
000), polyclonal rabbit anti-histone H3.3 (H3; 1:10,000), and
polyclonal rabbit anti-acetyl-histone H4 (acH4; 1:10,000)
from Millipore (Temecula, CA, USA). Monoclonal mouse
anti-acetylated tubulin (1:4000) was from Sigma-Aldrich (St.
Louis, MO, USA) and monoclonal mouse anti-α-tubulin
Fig. 1 Experimental design and flowchart. tg = PLP –αSynmice; non-tg
= C57Bl/6 mice; NaPB = sodium phenylbutyrate
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(1:500) from Abcam (Cambridge, UK). Amersham ECL don-
key anti-rabbit IgG horseradish peroxidase (HRP)-linked
whole antibody NA934 and Amersham ECL sheep anti-
mouse IgG HRP-linked whole antibody NA931 (1:10,000)
we r e f r om GE Hea l t h c a r e B i o - S c i e n c e s AB .
Immunohistochemistry involved the use of monoclonal
mouse anti-tyrosine hydroxylase clone TH-16 antibody
(1:1000) from Sigma-Aldrich, monoclonal anti-human-αSyn
15G7 (1:200) from Enzo (Lörrach, Germany), and biotinylat-
ed anti-mouse IgG (H+L) and biotinylated anti-rat IgG (H+L)
from Vector Laboratories (Burlingame, CA, USA).
Tissue Preparation
For immunohistochemistry, we perfusion-fixed the animals
under deep thiopental anesthesia (120 mg/kg body weight)
with 0.1 M PBS for 4 min followed by ice-cold 4% parafor-
maldehyde in 0.1 M PBS for 14 min. We dissected the brains
rapidly and postfixed them overnight at 4°C in the same
fixative.
For cryoconservation, we washed brains in 0.1 M PBS,
transferred to 30% sucrose in 0.1 M PBS until they sank,
and froze them in 2-methylbutan (−50°C). For long-term stor-
age, brains were maintained at −80°C.
For biochemical analysis, animals were perfused under
deep thiopental anesthesia with 15–20 ml PBS. Brains were
dissected, quickly frozen in liquid nitrogen, and stored at
−80°C. For radioimmunoprecipitation assay (RIPA) lysate
production, brain samples were homogenized with RIPA buff-
er (150 mM NaCl, 50 mM Tris–HCl, 1% deoxycholic acid,
1% Triton X-100, 1 mM ethylenediaminetetraacetic acid; pH
7.4) containing proteinase inhibitor cocktail (Complete
ULTRA tablet) for 1 min on ice by using IKA Ultra Turrax
T8 at level 5. Homogenates were centrifuged for 15 min at 16,
000 g (4°C). The supernatant representing RIPA fraction was
stored at −80°C for further Western blot analyses. For histone
fraction extraction, the pellet was quickly resuspended in
300 μl 0.2 M H2SO4, using the IKA Ultra Turrax T8 at level
5. The sample was allowed to incubate on a rotating wheel
overnight at 4°C. Samples were centrifuged for 10 min at 16,
000g (4°C), supernatant incubated for 30 min on ice with
equal amount of 66% trichloroacetic acid, and centrifuged
again, as described previously. The pellet was washed twice
with ice-cold acetone and centrifuged for 5 min at 16,000 g
(4°C). The pellet was let to dry for 20 min at room tempera-
ture, resuspended in Aqua dest. and stored at −80°C.
Immunoblotting
Protein concentration of RIPA lysates was measured by the
bicinchoninic acid protein assay and 20 μg of each sample
were loaded on 10% Bis-Tris gels from Novex Life
Technologies for electrophoretic separation. Proteins were
electrotransferred to nitrocellulose membranes (GE
Healthcare Bio-Sciences), blocked for 1 h with 2%
Amersham ECL Prime Blocking Agent in PBS containing
0.05% Tween-20 and incubated with primary antibody over-
night at 4°C followed by incubation for 1 h with the appropri-
ate HRP-conjugated secondary antibody. Detection with en-
hanced chemoluminescence reagent was performed with the
Fusion FX system for Western blot and gel imaging, and
quantified with FUSION CAPT V16.09b software (Vilber
Lourmat, Marne La Vallée, France). The expression lev-
el of α-tubulin was used for normalization of protein
expression in RIPA extracts and H3 expression level
in histone extracts was applied to normalize the expres-
sion values of acH3 and acH4.
Immunohistochemistry
Frozen brains were sliced serially to 40-μm sections
using a cryostat (Leica, Nussloch, Germany). A series
was mounted on microscope slides and used for stan-
dard cresyl violet staining. Further section series follow-
ed standard protocol for free-floating immunohistochem-
ical staining. In brief, they were incubated with 0.3%
H2O2 in PBS to quench endogenous peroxidase activity,
blocked in PBS containing 5% normal serum and 1%
BSA, and incubated with primary antibody in PBS con-
taining 1% normal serum and 1% BSA overnight at
4°C. This was followed by incubation with the appro-
priate biotinylated secondary antibody (1:200 in PBS
containing 1% normal serum and 1% BSA, for 1.5 h)
and Vectastain ABC reagent for 1 h. Stainings were
developed with 3,3’-diaminobenzidine, mounted on
gelat inated microscope sl ides, dehydrated, and
coverslipped with Entellan. Image analysis was per-
formed by using a light microscope (Nikon E-800 mi-
croscope) and a computer-assisted image analysis sys-
tem (Stereo Investigator Software; MicroBrightField
Europe e.K., Magdeburg, Germany). The analyses in-
cluded stereological counting of TH-positive or Nissl-
stained neurons and determining the density of 15G7-
positive aggregates per mm2 in SNc.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 5.0
(GraphPad Inc., La Jolla, CA, USA). If not indicated other-
wise, 2-wayANOVA and post-hoc Bonferroni’s correction for
multiple comparisons was applied when comparing two inde-
pendent factors (genotype and treatment). All data are repre-
sented as mean ± SEM, indicated in each figure. A p-value <
0.05 was set to determine statistical significance.
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Results
NaPB Treatment Improves Motor Performance
and Survival of Nigral Neurons in PLP–αSyn Mice
We found significantly shortened stride length in aged
PLP–αSyn transgenic mice (henceforth also called transgenic
MSA mice) compared with age-, sex-, and background-
matched nontransgenic control mice when recorded at 25
cm/s in the DigiGait system, confirming previous data [12].
Eight weeks of NaPB treatment restored the stride length of
the transgenic MSA mice similar to that of the nontransgenic
controls (Fig. 2a).
Next we sought to define the number of nigral neurons in
mice treated with NaPB as we have previously shown that
these transgenic MSA mice are characterized by mild nigral
neurodegeneration [12, 13]. Our analysis demonstrated im-
proved cell survival at the level of SNc after NaPB treatment.
In the untreated MSA mice, the number of tyrosine hydroxy-
lase (TH)-positive neurons in the SNc was significantly de-
creased when compared with nontransgenic controls (p <
0.001). In animals treated with NaPB, the number of TH-
positive neurons in transgenic MSA mice approximated the
levels in nontransgenic controls (Fig. 2b). To ensure that the
beneficial effect of NaPB in transgenicMSAmice reflects cell
survival and does not merely result from changed TH-
promoter activity [14], we performed standard Nissl staining
on the tissue, which confirmed the findings of TH immuno-
histochemistry (Fig. 2c).
NaPB-induced Nigral Neuroprotection is Linked to its
HDACi Activity and Reduction of αSyn Inclusions
in Transgenic MSA Mice
Next, we aimed to identify the mechanisms of neuroprotection
by NaPB in the transgenic mouse model of MSA. As a first
step to test the HDACi activity of NaPB, we analyzed the
levels of histone H3 and H4 acetylation in vehicle- versus
NaPB-treated mice. Treatment with the nonselective pan-
HDACi NaPB significantly increased the level of acH3 and
acH4 in MSA mice but had no effect on the histone acetyla-
tion in non-PLP–αSyn control mice (Fig. 3a–c).
The cytoskeletal protein α-tubulin represents a nonhistone
target for HDACs. Restored acetylation of nonhistone sub-
strates for HDACs that belong to classes I, II, and III can
modulate cellular signaling and exert neuroprotective effects
[15]. To determine whether cytoskeletal changes linked to α-
tubulin acetylation after NaPB treatment occur in the
PLP–αSyn mouse, we analyzed the expression levels of acet-
ylated α-tubulin. We detected no significant differences in the
acetylation profile of α-tubulin between NaPB- and vehicle-
treated mice (Fig. 3d, e). We conclude that changes in the
acetylation profile of α-tubulin do not account for the
findings.
Zhou et al. [16] suggested that treatment with NaPB in
animal models of PD may lead to a significant upregulation
of the DJ-1 protein linked to nigral neuroprotection. In keep-
ing with this notion, we hypothesized that NaPB upregulates
the endogenous antioxidant DJ-1 in the transgenic mouse
model of MSA, leading to the observed nigral neuroprotec-
tion. To address the question, we measured the levels of DJ-1
protein expression in vehicle- versus NaPB-treated animals.
We detected no significant changes in the expression levels of
DJ-1 between the treatment groups (Fig. 4).
Finally, NaPB could function as a chemical chaperone,
thereby decreasing pathological protein aggregation [17].
NaPB treatment in the transgenic mouse model of MSA sig-
nificantly reduced the density of αSyn-positive GCIs in SNc
compared with vehicle-treated animals (Fig. 5a–c). We iden-
tified a significant negative correlation between the number of
TH-positive neurons and the density of GCIs in SNc of the
transgenic MSA mice (Fig. 5d). The effects of NaPB treat-
ment on the levels of αSyn inMSAmice were also confirmed
by Western blotting (Fig. 5e).
Discussion
The current study provides, for the first time, evidence on the
beneficial effects of HDACi in aged PLP–αSyn mice. We
administered the drug daily for 8 weeks in mice overexpress-
ing human αSyn under the control of the PLP promoter in
oligodendrocytes [10], and reflecting GCI-like pathology
coupled with motor disability and nigral degeneration. We
demonstrated previously that these aged transgenic mice de-
velop shortened stride length compared with age-matched
wild-type controls [12]. The present study confirmed these
observations and showed that NaPB treatment significantly
improved hindlimb stride length. In agreement with the find-
ings on motor improvement, we have shown that NaPB treat-
ment protects nigral dopaminergic neurons in theMSAmouse
model. Thirty-five percent of dopaminergic TH-positive neu-
rons were lost in the SNc of PLP–αSyn mice, and this loss
was rescued successfully by NaPB treatment. It has been sug-
gested that HDACi are able to upregulate the activity of the
TH promoter [14]. It is possible to speculate that the increased
number of TH-positive neurons in SNc was actually related to
changed expression of TH. We confirmed the neuronal rescue
effect of NaPB in SNc of MSAmice in the current experiment
by estimation of the total number of neurons in the SNc in
classical Nissl staining. In summary, the rescue of nigral neu-
ronal integrity appeared in temporal sequence with gait im-
provement after treatment with NaPB in PLP–αSyn mice.
Our findings on nigral neuroprotection throughNaPB treat-
ment are in concert with observations in different PD models.
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Roy et al. [18] previously examined the efficacy of NaPB in 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxi-
cated C57Bl/6 mice and observed significantly less
neurodegeneration in the SNc after treatment. Striatal dopa-
mine was decreased by 76% in MPTP-intoxicated mice,
whereas NaPB treatment in MPTP-intoxicated mice limited
Fig. 2 Beneficial effects of sodium phenylbutyrate (NaPB) on motor be-
havior and nigral neurodegeneration in aged PLP–αSynmice. (A) Vehicle-
treated PLP–αSyn mice (tg; ntg + vehicle = 6) > 11 months of age showed
significantly reduced stride length (SL) of the hindlimbs compared with
vehicle-treated nontransgenic controls (non-tg; nnon-tg + vehicle = 11; ***p <
0.001). NaPB treatment of tg mice led to a significant improvement of the
stride length (##p < 0.01) back to the levels of non-tg controls, while stride
length was unaffected in non-tgmice receivingNaPB (ntg + NaPB = 4; nnon-tg
+ NaPB = 9). (B) Tyrosine hydroxylase (TH) immunohistochemistry re-
vealed significant loss of dopaminergic neurons in SNc of tg versus non-
tg mice receiving vehicle (ntg + vehicle = 10; nnon-tg + vehicle = 10;
***p <0.001). Treatment with NaPB rescued nigral dopaminergic
neurons in tg mice (ntg + NaPB = 8;
###p <0.001), while the treatment
had no effect in non-tg animals (nnon-tg + NaPB = 6). (C) Nissl staining
confirmed the observed effects of NaPB treatment as reported with TH
immunohistochemistry: there was significant loss of neurons in SNc of tg
versus non-tg mice receiving vehicle (ntg + vehicle = 4; nnon-tg + vehicle = 8; *p
<0.05). Treatment with NaPB rescued nigral neurons in tg mice (ntg + NaPB
= 6; ##p <0.01), while the treatment had no effect in non-tg animals (nnon-tg +
NaPB = 6). Groups were compared by 2-way analysis of variance followed
by post-hoc Bonferroni test. Data are presented as mean ± SEM. Scale bars
= 500 μm
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the decrease to 20–25%. Additionally, the study showed that
NaPB improved motor function in the MPTP model of PD
[18]. These effects have been repeatedly confirmed in studies
examining the neuroprotective effects of NaPB in toxin-
induced models of PD, including MPTP toxicity in mice
[16], 6-hydroxydopamine toxicity in rats [19], and rotenone-
induced nigral degeneration in mice [20].
Several candidate mechanisms, as listed further, have been
suggested to contribute to the neuroprotection triggered by
NaPB. We analyzed these mechanisms in relation to the nigral
neuroprotection in the transgenic PLP–αSyn mouse in order
to identify the therapeutic relevance of HDACi to MSA-
specific disease events (i.e., GCI-induced nigral degenera-
tion). In response to NaPB treatment in the transgenic MSA
mouse we identified increased acetylation levels of the histone
core protein H3. The effects of NaPB treatment on H3 acety-
lation are in line with previous studies. Mice treated with 6-
hydroxydopamine showed a general reduction in H3
Fig. 3 Histone deacetylase inhibitor activity of sodium phenylbutyrate
(NaPB) in aged PLP–αSyn mice (tg) and non-transgenic (non-tg) con-
trols. NaPB induced significant increase of (A) H3 acetylation (acH3),
and (B) H4 acetylation (acH4) in tg mice but had no effect on the acety-
lation of histones in non-tg mice. (C) Histone extracts were analyzed by
Western blotting and the band intensities for acH3 and acH4 were
normalized to the total H3 level. (D) NaPB treatment had no effect on
tubulin acetylation (acTub). (E) Radioimmunoprecipitation assay lysates
were analyzed by Western blotting and the intensity of acTub bands was
normalized to the total α-tubulin (αTub) expression. Treatment groups
were compared by t test. Data are presented as mean ± SEM (for all
groups n = 4)
Fig. 4 Sodium phenylbutyrate (NaPB) treatment does not affect levels of
DJ-1 expression in the midbrain of neither aged PLP–αSyn mice (tg) nor
non-tg controls. (A) NaPB had no significant effect of DJ-1 expression in
tg and non-tg mice. (B) Radioimmunoprecipitation assay lysates were
analyzed by Western blotting and the intensity of DJ-1 bands was nor-
malized to the total α-tubulin (αTub) expression. Groups were compared
by t test. Data are presented as mean ± SEM (for all groups n = 4)
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acetylation that was restored to normal levels after NaPB treat-
ment [19]. In an Alzheimer’s disease mouse model, H3
hyperacetylation upon NaPB treatment was linked to amelio-
ration of the cognitive deficits [11]. The current results suggest
that—linked to its HDACi activity—NaPB treatment may in-
terfere with the epigenetic control in the model of MSA-like
neurodegeneration and therefore lead to nigral neuroprotec-
tion. HDACi achieve histone hyperacetylation enhancing
gene transcription, owing to a widened chromatin structure
[3]. Therefore, HDACi might be able to reverse specifically
toxic effects of αSyn in the nucleus, where the protein has
been shown to interact with histones and carry out
hypoacetylation [9]. Increased H3 acetylation seems to be
involved in the neuroprotective effects of NaPB on MSA
pathogenesis; however, it is unclear at this stage, whether
neuroprotection is linked to direct epigenetic modifications
in the nigral neurons, or rather reflects epigenetic effects in
oligodendrocytes that provide improved trophic support for
degenerating neurons.
HDACs may interfere with acetylation of cytosolic pro-
teins like α-tubulin; however, NaPB treatment did not affect
the acetylation of α-tubulin in the transgenic MSA mouse.
Our findings are in concert with previous reports showing that
α-tubulin acetylation is carried out by HDAC6 and NAD-
dependent deacetylase sirtuin-2, which were not affected by
NaPB [21].
Next, we observed a strong reduction of the GCI load that
correlated with nigral neuroprotection in NaPB-treated trans-
genic MSA mice. Therefore, reduction of αSyn inclusion pa-
thology in the brains of MSAmice may be an important factor
Fig. 5 Sodium phenylbutyrate
(NaPB) treatment reduces the
density of glial cytoplasmic
inclusions (GCIs) in the midbrain
in aged PLP–αSyn mice. To
identify human αSyn-positive
GCIs in mice receiving (A)
vehicle or (B) NaPB, 15G7
immunohistochemistry was
performed. NaPB significantly
decreased the density of GCIs in
MSA mice when compared with
vehicle-treated animals, as shown
by t test analysis. Data are
presented as mean ± SEM, nvehicle
= 5; nNaPB = 4. (C) Linear
regression analysis showed
significant correlation between
the density of GCIs and the
number of dopaminergic neurons
in substantia nigra pars compacta
of MSA mice (D). Western blot
analysis of αSyn protein levels in
vehicle- and NaPB-treated MSA
mice confirmed the significant
reduction of the expression of
αSyn monomers (***p <0.001)
and oligomers (*p <0.05) after
NaPB therapy (E). Scale bars = 50
μm. TH = tyrosine hydroxylase
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for the neuroprotection achieved by NaPB treatment. Several
other strategies to reduce αSyn aggregation have been imple-
mented recently and support this hypothesis. Immunization
has been shown to reduce αSyn inclusions in models of α-
synucleinopathies and exert neuroprotection and phenotypic
improvement [22]. Small molecular tweezers, such as CLR01,
have been proposed to reduce αSyn aggregation linked to
neuroprotection and symptom amelioration in models of PD
[23]. The mechanism of reduction of αSyn aggregates in re-
sponse to NaPB treatment is not clear; however, previous
studies confirm this effect in various different models
[20, 24]. Apart from its epigenetic effects, NaPB may
play a role of a chemical chaperone that leads to ame-
lioration of protein aggregation in MSA similar to other
disorders [17].
Finally, previous work proposed that NaPB may trigger the
activation of endogenous antioxidants and therefore provide
neuroprotection [25]. Zhou et al. [16] showed that NaPB treat-
ment can upregulate DJ-1 expression levels in both C57BL/6
mice and the Thy1-Y39C αSyn mouse model of PD, which
was further linked to neuroprotection and reduced disease
progression [16]. However, we did not observe antioxidant
effects of NaPB treatment in aged transgenic MSA mice, as
measured by DJ-1 levels in SNc with the dosing regimen
applied here (different from the one in the study by Zhou et
al. [16]), suggesting that factors other than DJ-1-mediated cell
stress responses are pivotal for the neuroprotection reported in
the current experiment.
The PLP–αSyn mouse model of MSA has been previously
applied in several preclinical studies to screen for disease
modification by candidate drugs. In most of the cases the
accelerated model of MSA-like neurodegeneration was used,
that is, the pathology was modeled by a combination of the
transgenic αSyn overexpression and oxidative stress induced
by 3-nitropropionic acid [26–29]. This is the first study that
tests the efficacy of a drug in the pure transgenic model at a
late stage of the disease when functional changes and neuro-
degenera t ion l inked to the ol igodendrogl ia l α -
synucleinopathy occur progressively with aging. Several ex-
tensive studies have shown the face validity of the PLP–αSyn
mouse to replicate functional and neuropathological features
of human MSA [10, 12, 13, 30–34]. The current study pro-
vides the first proof for a predictive validity of the model by
identifying the relationship between the triggering factor
(αSyn-positive oligodendroglial inclusions) and the outcome
(nigral neurodegeneration and motor deficits) in response to a
therapeutic intervention [35].
In conclusion, our data show that HDACi leads to nigral
dopaminergic neuroprotection and amelioration of motor im-
pairments in a transgenic mouse model of MSA. We propose
that increased H3 acetylation interferes with reduction of ni-
gral GCI density and therefore contributes to the beneficial
effects of NaPB. Our results support a potential therapeutic
role of HDACi inMSA, as well as in otherα-synucleinoapthies
such as dementia with Lewy bodies, and PD.
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